【葛兰素史克的新型口服抗生素获FDA批准】美国食品药物管理局周二表示,批准葛兰素史克用于治疗无并发症泌尿道感染的新型口服抗生素,是次批准是公司今年预计推出的五款主要产品之一。葛兰素史克公司预计,上述抗生素将以Blujep为品牌名出售,加上其正在开发的另外两种抗感染药物每年的销售额将高达20亿英镑(约合26亿美元)。

金融界
26 Mar
美国食品药物管理局周二表示,批准葛兰素史克用于治疗无并发症泌尿道感染的新型口服抗生素,是次批准是公司今年预计推出的五款主要产品之一。葛兰素史克公司预计,上述抗生素将以Blujep为品牌名出售,加上其正在开发的另外两种抗感染药物每年的销售额将高达20亿英镑(约合26亿美元)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10